E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial
James A. de Lemos,C. Michael Gibson,Elliott M. Antman,Sabina A. Murphy,David A. Morrow,Kristin C Schuhwerk,Marc J. Schweiger,P Coussement,Frans Van de Werf,Eugene Braunwald +9 more
TL;DR: A strategy that uses a combination reperfusion regimen containing abciximab and a reduced-dose thrombolytic agent, followed by early adjunctive PCI, is associated with greater ST-segment resolution, which may reflect enhanced tissue level and microvascular perfusion.
Journal ArticleDOI
Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
Robert P. Giugliano,Roberto R. Giraldez,David A. Morrow,Elliott M. Antman,C. Michael Gibson,Satishkumar Mohanavelu,Sabina A. Murphy,Carolyn H. McCabe,Eugene Braunwald +8 more
TL;DR: Cardiogenic shock, age, and ICH were important independent correlates of 30-day and 1-year mortality in STEMI patients receiving fibrinolytic therapy as well as in-hospital non-ICH major and minor bleeding.
Journal ArticleDOI
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
Christina L. Fanola,Robert P. Giugliano,Christian T. Ruff,Marco Trevisan,Francesco Nordio,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +7 more
TL;DR: In VKA naive patients with AF, the TIMI-AF score can assist in the prediction of a poor composite outcome and guide selection of anticoagulant therapy by identifying a differential clinical benefit with a NOAC or VKA.
Journal ArticleDOI
Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction.
Rene Bruno,Pascale Baille,Sylvie Retout,Sylvie Retout,Nicole Vivier,Christine Veyrat-Follet,Ger-Jan Sanderink,Richard C. Becker,Elliott M. Antman +8 more
TL;DR: Enoxaparin clearance depends on body weight, and, therefore, weight-adjusted dosing is recommended to minimize interpatient variability in drug exposure and the risk of haemorrhage.
Journal ArticleDOI
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: Impact of age (A Meta-Analysis of a Decade of Trials)
Shaheeda Ahmed,Elliott M. Antman,Sabina A. Murphy,Robert P. Giugliano,Christopher P. Cannon,Harvey D. White,David A. Morrow,Eugene Braunwald +7 more
TL;DR: Elderly patients compared with younger patients still have a three to four fold increased risk of mortality and adverse events when treated with fibrinolysis and antithrombin therapy in the modern era, according to a meta-analysis of 11 published randomized clinical trials.